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Abstract 
Introduction: Androgenic alopecia (AA) patients usually have high levels of 
dihydrotestosterone on their balding scalp area. Currently, dutasteride (DST) is given 
orally and has systemic adverse effects; diminished sexual desire, increased 
depression and ejaculation disorder. Topical administration of DST is an appropriate 
drug-delivery strategy with the potential to reduce systemic side effect, skin irritation 
and cytotoxicity effects.  
Materials and method: Chitosan oligomer (CSO) conjugated with stearic acid (SA) 
or lauric acid (LA) was synthesised and characterised. Dutasteride-loaded 
nanostructured lipid carriers (DST-NLCs) were prepared using a melt-dispersion 
ultrasonication method. DST-NLCs were optimised using a design of experiments 
approach. DST-NLCs, uncoated and coated with CSO-SA or CSO-LA were 
characterised for particle size distribution, surface charge and morphology. In vitro 
release and permeation studies were performed. Cytotoxicity was investigated using 
human hair follicle dermal papilla cells, and skin irritation was performed using an 
EpiDerm™ RHE model. Cou-6 loaded NLCs were prepared and characterised before 
proceeding with the cell and skin uptake study. 
Results: CSO-SA and CSO-LA were successfully synthesised; confirmed using 
1
H 
NMR and FTIR. The mean size of DST-NLCs was significantly increased (p<0.05) 
when coated with 5% CSO-SA but not with 5% CSO-LA (p>0.05). The zeta 
potential changed from negative to positive charge when coating DST-NLCs with 
CSO-SA or CSO-LA. All formulations were physically stable over six months when 
stored at 4-8°C. However, DST-NLCs coated with CSO showed aggregation. All 
formulations exhibited rapid drug release. No dutasteride permeated through pig ear 
skin after 48
 
h for all formulations. The cytotoxicity (IC50) for DST nanoparticles, 
coated and uncoated, was greater than for DST alone (p<0.05). The in vitro skin 
irritation study indicated no irritation for all nanoparticle preparations. For the cell 
and skin uptake studies, all samples showed time-dependent skin and cell uptake.  
Conclusions: These stable, low cytotoxic and irritant, positively-charged DST-NLCs 
with CSO-SA or CSO-LA, represents a promising strategy for topical/ transfollicular 
delivery of DST. 
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Research Impact Statement 
 Androgenic alopecia is a common disorder affecting almost 50% of men in 
their lifetime due to the androgen effect. Based on the Euromonitor market study 
predicted in 2013, it was expected that the hair loss treatment would attract up to 
US$100 million in sales globally by 2016. Even though hair loss is not a life-
threatening disease, but it has a psychological and emotional effect, especially in 
young people. This study aims to prepare and characterise dutasteride-loaded 
nanostructured lipid carriers (DST-NLCs), coated with chitosan oligomer conjugated 
with stearic acid, and lauric acid to enhance local drug delivery and reduce toxicity.  
This study will help in our understanding of the potential of nanoparticle 
formulations for topical delivery of hair growth molecules, which will benefit society 
especially, androgenic alopecia patients, improving their quality of life. Currently, 
few products are available in the markets which are prescribed for the androgenic 
alopecia patient. Due to their systemic adverse effects, the delivery of dutasteride for 
promoting hair growth using topical route would be a great advance. Phase III 
clinical studies on the use of dutasteride for promoting hair growth have shown 
significant hair growth for the people with hair loss. Unfortunately, no topical 
product based on dutasteride has been approved.  
This research can generate good networks between researchers in the 
academia and people from industries whereby they can exchange the idea, skills and 
knowledge on the research and business areas. Also, this research can be one of the 
platforms for other molecules to be applied for topical or non-topical applications. A 
trained and skilled researcher who has cross-disciplinary generated from this study 
would be one of the main impacts on the academic area. In term of the economic, it 
would generate a knowledge transfer between researchers and industrial people who 
will lead to spin out companies, and the creation of new processes and products.  
. 
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1.1 Skin structure and function 
Skin is the largest, heaviest and most versatile organ of the human body. The 
vital roles of the skin are the protection of the body, regulation of body temperature 
and sensory perception. The skin protects the body from water loss and the 
possibility of access by potentially toxic compounds, allergens, irritants and microbes 
(Bartosova and Bajgar, 2012). To ensure these diverse functions can be fulfilled, 
healthy skin is needed. For an adult, the skin surface area is approximately 1.8 - 2.0 
m
2 
(Uchechi et al., 2014). Figure 1.1 shows the structure of the skin.  
 
 
 
Figure 1.1 Structure of skin (adapted from MacNeil, 2007) 
 
The skin consists of three main layers (Figure 1.2). The outermost layer is the 
epidermis which is made up of stratum corneum, stratum lucidum, stratum 
granulosum, stratum spinosum and stratum basal (Williams, 2018). The barrier 
properties of the skin are due to the stratum corneum. The stratum corneum is a very 
hydrophobic layer, comprising differentiated non-nucleated cells, corneocytes, filled 
with keratins embedded in the lipid domain (Godin and Touitou, 2007). The lipid 
domain is composed of equal proportions of ceramides, cholesterol and free fatty 
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acids (Pappas, 2009). The synthesis of these three components promotes the acidic 
condition of the skin.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Skin structure and layer (redrawn from Bensouilah and Buck, 2006) 
 
The second layer is dermis. The dermis is composed of connective tissues 
such as collagen fibrils and elastic tissues that mostly provide support, mechanical 
strength, elasticity and flexibility of the skin. The dermis is supplied with a reticulate 
network of blood vessels, lymphatic vessels, nerve endings, hair follicles, sebaceous 
glands and eccrine glands (Thakur et al., 2008). 
 
Finally, the inner layer of the skin is subcutaneous tissue or hypodermis 
which contains adipose cells in and between the connective tissue. The primary 
function of subcutaneous tissue is to provide insulation to the body (Williams, 2018).  
1.2 Hair  
The largest appendages, which consist of hair follicles and sebaceous glands, 
can provide ‘short cut’ routes which drugs can pass across the stratum corneum 
barrier (Williams, 2018). The hair follicle is an organ and part of the skin. It starts in 
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the dermis and goes through the outer part of the skin to the epidermis layer (Figure 
1.3). Hair consists of proteins, lipids, water, trace elements and pigments (Robbins, 
2012). The hair protein is called keratin. Hair can be divided into two types. First is 
vellus hair, appearing on the body, or hair that changes to terminal hair at puberty. 
The second is called terminal hair. Terminal hair may be short (eyebrows, ears, nose) 
and long (head hair, beard, underarm, pubic area).  
 
 
 
 
 
 
 
 
 
Figure 1.3 Structure of the hair follicles (adapted from Adolphe and Wainwright, 
2005) 
 
Hair that is visible above the skin is called the hair shaft. It consists of cuticle, 
cortex and medulla. Previous studies have found the hair diameter on the scalp and 
face differ (Tolgyesi et al., 1983). The normal adult hair shaft diameter (Caucasian) 
is approximately 70 µm, whereas in the beard it is 126 µm. These have made skin 
appendages (sweat gland and hair follicle) which is only 0.1% to 1% of the area of 
the skin (Schaefer and Redelmeier, 2001) used as a follicular route for targeted 
delivery of drugs. 
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Hair that is invisible or within the skin is called the hair root. The bulbous end 
of the hair root is called the hair bulb (Williams, 2018). All biological processes 
including cell division happen in this part. The hair bulb is positioned in a tubular 
pocket called the hair follicle. Human hair follicles are one of the organs that are 
affected by hormones such as androgens (Randall et al., 1991). Androgen promotes 
hair growth and also sometimes inhibits scalp hair growth causing androgenetic 
alopecia (AGA). As it is specific to the hair follicle itself, the response to androgens 
varies with the body site. In the case of AGA, androgens cause the miniaturisation of 
the scalp hair follicle (Hibberts et al., 1998). 
1.3 Hair growth cycles 
Hair is produced by the hair follicle and undergoes a cycle with different 
phases. It starts at the anagen phase, then passes through catagen and lastly telogen 
phases. All hair growth phases in the body occur at the same time; one hair might be 
in the anagen phase and others in the catagen or telogen phase. The original lower 
follicle will be destroyed, and the new follicle will regenerate to form a new hair 
(Randall and Botchkareva, 2008).  
Figure 1.4 shows the cycles of hair growth in the normal human body. 
Different areas have different hair growth cycle. Hair is produced in the anagen 
phase or so-called growth phase. Scalp follicles have the longest anagen phases, 
lasting up to several years (Randall, 2008). Once hair reaches its full length in the 
anagen phase, then the catagen phase (regression) will take place, in which cell 
proliferation, differentiation, and pigmentation will stop, and extensive apoptosis 
occurs, and the dermal papilla shrinks (Randall, 2008). The catagen phase normally 
takes 1 to 2 weeks. In the catagen stage, the hair is fully keratinised and a specialised 
structure, the club hair is formed and moves upwards (Randall and Botchkareva, 
2008). After this, the telogen phase takes over, which lasts for several months. 
During the telogen phase, the round-shaped dermal papilla is closely situated near to 
the secondary hair germ keratinocytes containing hair follicle stem cells. In an early-
mid anagen phase, a new lower follicle develops inside the same dermal sheath, and 
the new hair grows into the original upper follicle, and the existing hair ejected 
(Randall and Botchkareva, 2008).  
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Figure 1.4 The hair follicle growth cycle (adapted from Randall and Botchkareva, 
2009) 
1.4 Mechanism of hair loss  
Most problems associated with hair relate to either hirsutism (excessive hair 
growth) or alopecia. Alopecia is a common medical term for hair loss or baldness. 
Baldness which is affected by androgens is called AGA, also known as male pattern 
hair loss (MPHL) or female pattern hair loss (FPHL) (Kaufman, 2002). Testosterone 
and dihydrotestosterone are the major androgens that regulate the hair growth.  
Dihydrotestosterone (DHT) has approximately a five-fold greater affinity for 
the androgen receptor than testosterone (Kaufman, 2002). In hair loss patients, the 
5α-reductase enzyme acts as a catalyst that converts testosterone, which is the 
primary androgen, to the more potent androgen, DHT which makes the hair follicle 
miniaturise and shed hair (Olsen et al., 2006).  
Figure 1.5 shows the hair loss cycle for a patient with hair loss. Due to the 
effect of the potent androgen (DHT), their normal hair starts as long, thick and 
pigmented, then changes to be thin, short and less pigmented at the end of the 
process. The new hair colour becomes less pigmented from one cycle to another, the 
hair shaft becomes thinner, and there is the appearance of baldness. Two isozymes 
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participate in androgen synthesis; namely, Type I 5α-reductase isozyme which is 
present in the skin, hair follicles and sebaceous glands, liver, prostate, and kidney and 
Type II 5α-reductase isozyme which is present in hair follicles, male genitalia and the 
prostate (Russell and Wilson, 1994; Kandavilli et al., 2010). Both these isozymes are 
involved in steroid metabolism and interact with the androgen receptors. In androgen 
synthesis, the 5α-reductase enzyme acts as catalyst converting testosterone to the 
more potent dihydrotestosterone. By introducing a 5α-reductase inhibitor, the 
conversion of testosterone to DHT can be decreased and reduce hair loss.        
 
 
 
 
 
 
 
 
Figure 1.5 Hair loss cycle in patients with male pattern baldness (adapted from 
Randall, 2010) 
1.5 Anti-androgenic activity for treating hair loss 
Hair loss is not a life-threatening disease, but has an emotional impact and 
affects certain individuals, especially young people and they may experience 
psychological distress (Hunt and Mchale, 2005). Androgenic alopecia (male pattern 
baldness) is a common disorder affecting almost 50% of men in their life (Yassa et 
al., 2011) due to effect from androgen. Androgen is one of the prerequisites for male 
pattern baldness (Randall and Botchkareva, 2008). Normally, patients with 
androgenic alopecia have higher levels of DHT (dihydrotestosterone) and 5α-
reductase enzyme activity on their balding scalp area than those with a non-balding 
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scalp area (Hibberts et al., 1998). Figure 1.6 shows the circulation of androgens in 
the hair follicles. Testosterone (T) is mainly secreted by the Leydig cells of the testes 
of males and a lesser amount by the ovaries of female (Brownlee et al., 2005).  
 
 
 
 
 
 
 
 
 
Figure 1.6 The action of androgen in the hair follicle (redrawn from Randall and 
Botchkareva, 2009)  
 
Testosterone will circulate in the blood and enter the hair follicle through the 
dermal papilla’s blood supply and interact with the androgen receptors in the dermal 
papilla cells. Several studies have focussed on the inhibition of the activity of the 5α-
reductase enzyme, either by using natural extracts or drugs. One example of natural 
extract for 5α-reductase inhibitor was the use of fatty acids (Liu et al., 2009); those 
with C12-C16 and C=C double bond which enhanced Type II 5α-reductase inhibition 
activity. Finasteride which has Type II 5α-reductase inhibitor activity is approved by 
the FDA to treat benign prostatic hyperplasia and male pattern baldness. Dutasteride 
is approved for treating benign prostatic hyperplasia (BPH) and has both Types I and 
II 5α-reductase inhibitor. Finasteride and dutasteride are discussed in detail in 
Section 1.8.2 and 1.8.3 respectively. 
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1.6 Market overview of hair loss products 
Figure 1.7 shows the estimated size of the global hair care market in 2013 
from 2006 to 2016 (Euromonitor International, 2013). Hair care products comprise 
products that promote health; hair nourishment, prevention of hair damage and hair 
loss treatment.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Size of the global hair care market in 2006, 2011 and the estimated 
market in 2016 (in billion U. S. dollars) (adapted from Euromonitor International, 
2013) 
 
From this data, the sales of the hair loss treatments are dominated by 
minoxidil (Regaine®, Johnson and Johnson) which exhibits a significant sales 
growth especially in Western Europe (Euromonitor International, 2013). Minoxidil is 
an over-the-counter drug and has been approved for treating hair loss in both men 
and women. However, some people use cosmetic products to treat hair loss rather 
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than pharmaceutical products due to their adverse effects. In this case, cosmetics are 
defined in Regulation (EC) No. 1223/2009 as: 
"any substance or mixture intended to be placed in contact with the external 
parts of the human body (epidermis, hair system, nails, lips and external genital 
organs) or with the teeth and the mucous membranes of the oral cavity with a view 
exclusively or mainly to cleaning them, perfuming them, changing their appearance, 
protecting them, keeping them in good condition or correcting body odours.” 
(European Commission, 2009). 
Cosmetics or drugs used for treating hair loss are not permanent and their 
activity is reversible, which means when someone uses the product; hair loss will 
decrease or stop, but when they stop using the product, then the hair loss returns. To 
reduce this problem, an effective delivery system for a drug acting as a potential hair 
growth promoter should be designed to have a long-lasting effect such as having 
controlled release properties which is targeted to the hair follicle area and at the same 
time reduce the adverse effects. 
1.7 Delivery of drugs to the skin 
Many studies have been conducted to deliver drugs to the transfollicular 
region (Bhatia et al., 2013; Mittal et al., 2015). Figure 1.8 shows the potential 
penetration pathways of a drug through the skin. The drug can pass either through the 
skin barrier (No. 1 - 3) or to the transfollicular area (A - D). Drug delivery through 
the skin offers convenience to the patient, is pain-free and allows self-administration, 
and may eliminate frequent administration especially when long-term treatment is 
needed (Paudel et al., 2010). 
The transfollicular route has shown promise for delivery; particulate delivery 
would be ideal by allowing deep intrafollicular penetration, sustained release and 
selectively targeted delivery (Patzelt and Lademann, 2013). The size of particulate 
materials is one of the key criteria to deliver the drug to the transfollicular area. Hair 
follicles have a size range from 10 - 70 μm depending on the hair type, location and 
race (Singh et al., 2000) making it a suitable site for delivering nanoparticles to the 
dermal papilla cells for hair growth products.  
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Previous research has found that, applying 320 nm fluorescence dye-
containing nanoparticles, and massaging the area enhanced the penetration for up to 
10 days (Lademann et al., 2007); with nanoparticulates of dye penetrating deeper 
than the dye in solutions. 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic illustration of the potential penetration pathways of drugs 
through the skin (redrawn from Patzelt and Lademann, 2013) 
 
Lipophilic vehicles rather than hydrophilic are able to improve the delivery of 
drug to the skin (Motwani et al., 2004), and many  studies have been conducted using 
lipid-based vehicles for dermal delivery (Doktorovova et al., 2011; Wang et al., 
2012; Uprit et al., 2013; Montenegro et al., 2016). Due to the occlusive properties of 
lipid nanoparticles, an increased skin hydration effect is observed (Hommoss, 2008). 
Previous studies found that a lipid film formed on the top of the skin, and the 
subsequent occlusion effect was reported for lipid nanoparticles (Müller et al., 2002; 
Wissing and Müller, 2003; Escobar-Chávez et al., 2012). Particles smaller than 400 
nm containing at least 35% lipid of high crystallinity have been most effective for the 
occlusive properties (Wissing and Müller, 2003).  
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Figure 1.9 shows that the occlusion factor of lipid nanoparticles depends on 
the sizes; reducing the particle size leads to an increase in particle number, the film 
becomes denser (left) and therefore the occlusion factor increases. Other criteria on 
the occlusion factor have been considered, such as identical lipid content; increasing 
the lipid concentration increases particle number and density of the film (right) which 
also leads to a higher occlusion factor (Pardeike et al., 2009). In solid lipid 
nanoparticles (SLN) or nanostructured lipid carriers (NLC) system, the skin 
hydration after applying these nanoparticles leads to a reduction of corneocytes 
packing and an increase in the size of the corneocytes gaps and facilitate the 
percutaneous absorption and drug penetration to the deeper skin layers (Hommoss, 
2008). 
 
 
 
 
 
 
Figure 1.9 The occlusion factor of lipid nanoparticles depends on different sizes 
(redrawn from Escobar-Chávez et al., 2012) 
 
 Campbell et al., (2012) investigated the deposition of nanoparticles in 
mammalian skin and found that nanoparticles (mean size of 20 – 200 nm) cannot 
penetrate beyond the superficial layers of the barrier.  Figure 1.10 shows the intensity 
of fluorescence nanoparticles at different sizes. Even at the smallest mean size of 
nanoparticles (20 nm), there is no penetration of nanoparticles to the deeper layer of 
the skin. This result proved that nanoparticles could not penetrate the skin barrier, but 
it is useful as skin surface reservoirs to control the drug release over time (Campbell 
et al., 2012).  
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Figure 1.10 Fluorescence intensity of different sizes of nanoparticles (without 
removing the stratum corneum) (modified from Campbell et al., 2012) 
 
 Fang et al. (2014) reported the mechanism of skin permeation by drug-loaded 
NLCs (Figure 1.11). As mentioned before, occlusion factor which increases 
hydration of the stratum corneum (SC) become the main factor that can reduce the 
corneocytes packing and increase drug permeation (Fang et al., 2014). These findings 
suggest that nanoparticles could go deep in the skin and systemic circulation through 
transfollicular region as seen in Figure 1.11. 
 
 
 
 
 
 
Figure 1.11 Mechanism of drug permeation by NLCs (redrawn from Fang et al., 
2014) 
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1.8 Drugs used for treating hair loss 
1.8.1 Minoxidil 
For many years, minoxidil has been the first-choice for topically applied drug 
recommended by medical practitioners to treat hair loss for both men and women. 
Currently, Rogaine® (USA) or Regaine® (Europe and UK) is an approved hair-loss 
product based on minoxidil which is available on prescription and as an over-the-
counter medication. Minoxidil (Figure 1.12), a pyridine derivative drug was used in 
the 1970s as a treatment for hypertension in patients where therapy had failed with 
multidrug regimens (Messenger and Rundegren, 2004; Sica, 2004). In 1988, 1% 
minoxidil mixed with an alcohol-based carrier was approved by the FDA to treat 
alopecia in men.  
In a 12-month randomised double-blind trial of 150 men, 82% of the 
minoxidil group increased hair count (Kreindler, 1987). Sato et al., (1999) used 
cultured human dermal papilla cells from the balding scalp and found that minoxidil 
increased 17β-hydroxysteroid dehydrogenase activity by approximately 40% but had 
an insignificant effect on 5α-reductase activity and such as the mechanism of 
minoxidil action remains unknown (Silva et al., 2009). Another study  (Han et al., 
2004) found minoxidil prolonged the anagen phase where the dermal papilla cells 
proliferated and had an anti-apoptotic effect on dermal papilla cells. 
 
 
Figure 1.12 Chemical structure of minoxidil 
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1.8.1.1 Nanocarrier delivery of minoxidil and minoxidil derivatives 
In order to overcome the severe adverse reaction such as scalp dryness, 
irritation from propylene glycol-water-ethanol ingredients in the current minoxidil 
products, several studies have investigated the delivery of minoxidil using 
nanoparticle formulation. Nanostructured Lipid Carrier (NLCs) have been used for 
the delivery of minoxidil (Silva et al., 2009) for promoting hair growth, with a 
particle size of approximately 250 nm before adding to a hydrogel; particles 
remained below 500 nm when incorporated in the hydrogel. These formulations of 
minoxidil-NLCs hydrogel were a promising alternative to the conventional alcoholic 
solutions, as the drug is physically entrapped within the lipid matrix which can be 
useful to increase the bioavailability for skin delivery (Silva et al., 2009). No efficacy 
study on hair growth activity between the minoxidil-NLCs hydrogel and 
conventional minoxidil solutions was conducted. However, this formulation 
approach would help in reducing the risk of occurrence of adverse side effects, such 
as skin dryness and irritation. 
The Globally Harmonized System of Classification and Labeling of 
Chemicals (GHS) defines skin irritation as “the production of reversible damage to 
the skin following the application of a test substance for up to 4 hours” and skin 
corrosion as “the production of irreversible damage to the skin; namely, visible 
necrosis through the epidermis and into the dermis, following the application of a test 
substance for up to 4 hours” (United Nations, 2013). Padois et al., (2011) used solid 
lipid nanoparticles (SLNs) as a carrier for minoxidil and found SLNs suspensions 
which was approximately 190 nm of particle size proved efficient as commercial 
solutions for skin penetration; and were non-corrosive while commercial solutions 
presented a corrosive potential. 
Some examples of minoxidil-loaded nanoparticulate carriers include research 
by Aljuffali et al. (2014), which used squalene-based NLCs for targeted drug 
delivery, known as “squarticles” and delivered minoxidil together with 
diphencyprone. The size was approximately 177 nm for the NLCs-based carrier. The 
encapsulation efficiency and zeta potential for minoxidil-loaded squalene NLCs were 
63.3% and -54.0 mV respectively. They found that compared to the free control 
(drugs in 30% propylene glycol in water), squarticles-NLCs reduced minoxidil 
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penetration through the skin, indicating minimised absorption in the systemic 
circulation. The result also showed an improvement of drug deposition by 2-fold in 
the skin, using an in vitro skin absorption test and good tolerability of squarticles to 
skin based on the in vitro papilla cell viability and in vivo skin irritancy tests in nude 
mice. 
 Matos et al. (2015) formulated minoxidil sulphate-loaded chitosan 
nanoparticles (MXS-NP) which demonstrated sustained drug release (5-fold) 
compared to drugs in solutions. The MXS-NP formulation (chitosan/MXS; 1:1 w/w) 
had mean diameter 236 nm and positive zeta potential. They found that the drug 
permeation studies through the skin in vitro showed that MXS-NP application 
resulted in a 2-fold increase in MXS in uptake hair follicles after 6 h in comparison 
to the control solution.  
1.8.2 Finasteride 
Finasteride, (Figure 1.13) an anti-androgen steroidal drug has been used 
widely to treat patients with benign prostatic hyperplasia. A clinical open, 
randomised, parallel-group study for 12 months on 100 male patients with 
androgenic alopecia to investigate the efficacy of oral finasteride (1 mg per day), 
topical 2% minoxidil solution and topical 2% ketoconazole shampoo alone and in 
combination was conducted (Khandpur et al., 2002). The results demonstrated a 
significant increase in hair growth between a combination group having finasteride 
orally (1 mg) and 2% minoxidil (topically) and finasteride (orally) alone (Khandpur 
et al., 2002).  
 
 
 
 
Figure 1.13 Chemical structure of finasteride 
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1.8.2.1 Nanocarrier delivery of finasteride 
Several studies have been conducted using nanoparticle formulations of 
finasteride for topical delivery. Madheswaran et al., (2013) prepared liquid 
crystalline nanoparticles from monoolein, with size 154 – 170 nm which showed a 
potential for topical delivery of finasteride. The addition of different types of 
additives (glycerol, propylene glycol, and polyethylene glycol 400) had little or no 
influence on the size. The formulations produced slow release profiles and high 
permeation to the dermis. The release profile was significantly altered with the 
addition of different additives. Formulation with monoolein exhibited skin 
permeation which increased significantly with the inclusion of glycerol, propylene 
glycol, and polyethylene glycol 400, while it decreased with the addition of oleic 
acid. The release rate of finasteride increased when glycerol, propylene glycol, or 
polyethylene glycol 400 was added and decreased with the addition oleic acid.  
Gomes et al. (2014) formulated lipid nanoparticles of finasteride with mean 
size around 200 nm and stable up to 28 days. Penetration studies using pig ear skin 
found that only a small amount of finasteride crossed the skin, suggesting the 
suitability of this formulation for dermal delivery of anti-alopecia active compounds. 
Caon et al. (2014) found chitosan coated polymersomes of finasteride 
interacted more strongly with the skin components than non-coated formulations due 
to the positive surface charge. It was observed that the addition of chitosan 
contributed to an increase in the accumulation of finasteride in the epidermis. It was 
proposed that the particles (mean diameter of 180 - 404 nm) were preferentially 
accumulated in the follicular openings and that follicular localization was favoured 
by the smaller particle size, which would be more easily transported via the follicular 
route than the larger size.  
1.8.3 Dutasteride 
Dutasteride, approved for treating benign prostatic hyperplasia also affects 
hair growth. Due to its androgenic activity, dutasteride can only be taken by male 
patients. Dutasteride (MW = 528.5 g/mol) (Figure 1.14) is classified as Class II/IV in 
the Biopharmaceutics Classification System (BCS) (Tiwari et al., 2014). It has very 
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low water solubility (0.038 ng/mL, Log P = 5.09 and pKa = 13.5) and high solubility 
in ethanol (44 mg/ml) and methanol (64 mg/ml) at 25° C and has a half-life of 
approximately 3-5 weeks (GlaxoSmithKline Inc., 2013). 
In 2009, dutasteride (0.5 mg daily orally intake) was approved in Korea for 
treating hair loss in men (Harcha et al., 2014), but until now no dutasteride-based 
product been approved for androgenic alopecia in Europe or USA. However, it is 
commonly prescribed as an off-label for hair loss treatment (oral administration) in 
the USA and Europe. This product is swallowed without chewing, crushing, or 
opening the capsule because it might irritate the lips, mouth, and throat. The 
prescribed dosage for treating benign prostatic hyperplasia (BPH) is 0.5 mg per day 
(GlaxoSmithKline Inc., 2013). 
 
 
Figure 1.14 Chemical structure of dutasteride 
 
Olsen et al. (2006) found dutasteride increased scalp hair growth in men with 
hair loss, at 2.5 mg of dutasteride (orally), it and was superior to finasteride (5 mg) 
(orally) at 12 and 24 weeks. Eun et al. (2010) used dutasteride for treating hair loss in 
male patients at 0.5 mg daily orally and reported that the dutasteride group had 
significant hair growth compared to the placebo group within six months. Another 
study (Stough, 2007) reported evidence that dutasteride significantly reduced hair 
loss progression in men with male pattern hair loss when tested in a randomised 
study in 17 pairs of identical twin males for 1 year period. They found that treatment 
with dutasteride (0.5 mg/day orally) slowed the progression of hair loss and enhanced 
hair growth compared to treatment with placebo. In 2014, a randomised, active- and 
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placebo-controlled study of dutasteride versus placebo and finasteride in the 
treatment of 917 male subjects with androgenetic alopecia was conducted by Harcha 
et al. (2014). They found that dutasteride 0.5 mg significantly increased the hair 
count, width diameter and improved hair growth at week 24 compared with 
finasteride and placebo. 
1.8.3.1 Nanocarrier delivery of dutasteride 
Based on the summary of product characteristics for oral dutasteride 
(Avodart®), the side effects of taking oral dutasteride are: it may increase the risk of 
development of high-grade prostate cancer, decrease libido, and may cause breast 
enlargement and ejaculation disorders (GlaxoSmithKline Inc., 2013). Dutasteride has 
a toxicity effect on the skin, with multiple red areas produced in the skin (animals at 
40 mg/kg) suggesting that dutasteride is a dermal irritant (GlaxoSmithKline Inc., 
2013). In order to reduce these side effects, drug delivery with sustained release 
should preferably target the skin, especially to the hair follicle. Delivery of 
dutasteride using nanocarriers has been studied by the oral route with little research 
of topical delivery (Table 1.1).  
Previous research on topical delivery has used a liposome system (Sharma et 
al., 2011). The liposomes produced significantly higher skin permeation of 
dutasteride through excised abdominal mouse skin compared to a hydro-alcoholic 
solution and conventional gels. Ansari et al. (2013) prepared different ratios of oleic 
acid and eucalyptus oil to prepare nanoemulsion to deliver dutasteride to the skin. 
The mean size range was around 18 - 213 nm, no measurements were undertaken on 
zeta potential, entrapment efficiency, and drug loading. Madheswaran et al. (2015) 
used monoolein to produce dutasteride nanoparticles, with their surface modified 
using different concentrations of chitosan (low molecular weight) to give a positive 
charge.  The particle size was 239 - 259 nm, with mean zeta potential of +19.8 to 
+48.5 mV. The surface modified liquid crystalline nanoparticles enhanced 
transdermal delivery of dutasteride and increased the permeation of dutasteride using 
a porcine skin (700 – 800 µm thickness). Release studies on this formulation 
produced the cumulative amount of dutasteride released only about 5% after 24 h. 
The highly lipophilic nature of dutasteride, which had a stronger interaction with 
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lipid inside the nanoparticles produced slower release compared to finasteride 
(Madheswaran et al., 2015). 
 
Table 1.1 Published studies on the delivery of dutasteride using different types 
of nanocarriers 
Delivery system Particle Size Application Authors 
Liposome 1.82 ± 0.15 μm Topical for 
dermal 
delivery 
Sharma et al. 
(2011) 
Eudragit E® nanoparticles 62.2 – 180.6 nm Oral Park et al. 
(2013) 
Hydroxypropyl- 
β-cyclodextrin nanostructures 
<160 nm Oral Kim, (2013) 
Self-microemulsifying drug 
delivery system (SMEDDS) 
43.9 nm Oral Kim et al. 
(2015) 
Self-microemulsifying drug 
delivery system (SMEDDS) 
35.3 nm Oral Choo et al. 
(2013) 
Nanoemulsion 58.8 – 88.7 nm Topical for 
systemic 
delivery 
Sajid et al. 
(2014) 
Liquid crystalline nanoparticles 197.9 ± 2.5 nm Topical for 
dermal 
delivery 
Madheswaran 
et al. (2015) 
 
1.9 Positively-charged nanoparticles 
Nanoparticles having a positive surface charged have received great interest 
in drug delivery, especially for topical and transfollicular delivery, where hair and the 
lipid layer in the SC contain high ratio of negatively-charged lipids (Bhushan, 2010; 
Madheswaran et al., 2015). For instance, the anionic surfactant is often added in 
shampoos to remove grease from the hair. The surfactant has two different regions; 
one region is soluble in water (hydrophilic) and the other region is soluble in the 
greasy material (lipophilic). The lipophilic/hydrophobic part will encircle the greasy 
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matter, and the other part (negative-charged) will repel the fibres because hair fibres 
are negatively-charged, and remove the greasy material easily. 
On the other hand, cationic surfactants are normally added to hair 
conditioners to neutralise the charge of hair after washing. Based on this, many 
studies on positively-charged nanoparticles have been undertaken in order to promote 
interaction with the negative target site, especially for dermal/transdermal and 
transfollicular delivery (Şenyiǧit et al., 2010; Gelfuso et al., 2011; Ridolfi et al., 
2012; Özcan et al., 2013; Madheswaran et al., 2015). 
1.10 Chitosan 
Chitosan is a natural polymeric material being used increasingly by the 
pharmaceutical industry. It contains free amine groups, and this makes it is insoluble 
in water (water-soluble only at pH<6) (Sogias et al., 2010).  Chitosan oligomers or 
chitosan oligosaccharide (Figure 1.15) are the hydrolysates of chitosan, mainly made 
up of -1,4 linked D-glucosamine and partially of -1,4 linked N-acetyl-D-glucosamine 
(Ibrahim et al., 2016). Chitosan oligomer has been used widely for different 
bioactivity such as antibacterial (No et al., 2002; Merchant et al., 2014; Yildirim-
Aksoy and Beck, 2017), antitumour activity (Jeon and Kim, 2002; Hu et al., 2009; 
Xie et al., 2012), anti-cancer activity (Nam et al., 2007a; 2007b), wound healing 
activity (Kang et al., 2016) and antioxidant activity (Sun et al., 2007). 
 
 
 
 
 
 
Figure 1.15 Structure of chitosan oligomer 
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In this project, chitosan oligomer (Carbosynth Ltd, United Kingdom) with 
molecular weight less than 3 kDa and 85% deacetylation degree was chosen. This 
chitosan is positively charged, which is likely to be advantageous for skin and hair,  
such skin and hair are negatively charged and will be attracted to positively charged 
moieties (Bhushan, 2010). Mittal et al. (2015) demonstrated that a nanoparticle 
formulation of antigen ovalbumin with chitosan increased follicular uptake when 
compared to a nanoparticle formulation without chitosan.  
1.10.1 Hydrophobic derivatives of chitosan  
Table 1.2 shows the potential delivery of drugs by using different types of 
chitosan conjugated with a hydrophobic chain (fatty acid). From Table 1.2, it can be 
seen that chitosan conjugated with fatty acid has been employed in many areas using 
nanoparticles and micellar systems. 
 
Table 1.2 Chitosan conjugation with different type of fatty acids and their 
application 
Delivery system Chitosan and Fatty acid Application Authors 
Micelles Chitosan 18 kDa and 
stearic acid 
Brain targeting Xie et al. (2012) 
Immobilization Chitosan LMW and lauric 
acid 
Osteoblast 
proliferation and 
antibacterial 
Zhao et al. (2014) 
Micelles Chitosan 5 kDa and stearic 
acid 
Oral delivery Li et al. (2010) 
Micelles Chitosan 9.2 kDa and 
stearic acid 
Anti-tumour 
activity 
Hu et al. (2009) 
Nanoparticles Chitosan 9.2 kDa and oleic 
acid 
Optical 
MR/Imaging 
Lee et al. (2011) 
Micelles Glycol chitosan  different 
MWs with palmitic acid 
(GCPQ) 
Oral, ocular, 
parenteral 
Uchegbu et al. 
(2014) 
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The surface activity of chitosan (non-conjugated) is low as it does not possess 
any hydrophobic portions and can be improved by chemical modifications at its 
glucosidic group with a hydrophobic substituent (Cheung et al., 2015). Szymańska 
and Winnicka (2015) reported chemical crosslinking with chitosan as a strategy to 
increase the stability of chitosan, whereby the stability of modified chitosan was 
based on the covalent bonds, and also interactions—hydrogen or hydrophobic bonds.  
 Xie et al. (2012) prepared chitosan oligosaccharide (MW 18 kDa) conjugated 
with stearic acid (CSO-SA) for brain targeting. The blood-brain barrier (BBB), 
makes it difficult for the drug to penetrate, however, the delivery of doxorubicin in a 
CSO-SA micellar system was beneficial. The micellar system (22 nm sizes; zeta 
potential +36 mV) demonstrated high drug loading and a slow release pattern. High 
amounts of doxorubicin were found in the brain and low amounts accumulated in the 
heart. This result was due to the ability of micelles to transport across the blood-brain 
barrier and into the brain (Xie et al., 2012). The lower toxicity of CSO-
SA/doxorubicin micelles than doxorubicin in solutions might be relevant with a slow 
release of doxorubicin from micelles (Xie et al., 2012). 
1.11 Nanoparticulate dermal drug delivery 
Topical application of drugs has many advantages especially reducing 
systemic effects and targeting affected local areas, such as for skin diseases. The 
stratum corneum (SC) provides the main barrier function of skin, limiting the loss of 
essential substances from inside the body and reducing chemically or toxic materials 
entering the body (Trommer and Neubert, 2006). Even though the drug in the 
formulation for hair loss therapy should ideally target the transfollicular region, drugs 
will also likely permeate through the dermal or transdermal regions which represent 
the main permeation pathways. Due to the limited permeability of the SC (the drug 
should be in low molecular weight and moderate lipophilicity), several methods have 
been employed to enhance the delivery of the drugs to the skin. These include 
chemical permeation enhancers such as fatty acids, urea, phospholipids, alcohols, 
amide, and sulfoxides and physical permeation enhancement such as iontophoresis, 
sonophoresis, ultrasound and microneedles (Finnin and Morgan, 1999; Pathan and 
Setty, 2009; Akhtar et al., 2011; Shaji and Varkey, 2012). 
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Other skin penetration enhancers, more recently investigated are micro or 
nanoscale size drug formulations, such as liposomes, polymeric nanoparticles, 
nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers (Müller et 
al., 2002; Sintov and Shapiro, 2004; Guterres et al., 2007; Escobar-Chávez et al., 
2012; Wang et al., 2012; Gomes et al., 2014). Mahe et al., (2009) found the particles 
of approximately 200 nm mean sizes applied to the skin were found around the hair 
follicles. Further studies reported that particles with a size approximately 300 nm 
were found in the transfollicular region (Mittal et al., 2015). These studies suggest to 
deliver the drug into the hair follicle regions, a size of particles in the range of 200-
300 nm is appropriate.  
1.11.1 Liposomes 
Liposomes, sphere-shaped vesicles with mean size 30 nm to several 
micrometres, produced by self-forming enclosed lipid bilayers upon hydration 
consisting of one or more phospholipid bilayers, were first described in the mid-60s 
(Akbarzadeh et al., 2013). Liposome formulations consist of one or more non-toxic 
natural phospholipids such as soy phosphatidylcholine and egg phosphatidylcholine 
or a synthetic phospholipid such as distearoyl-phosphatidylcholine (Figure 1.16).  
 
 
 
 
 
 
Figure 1.16 Schematic representation of a liposome, showing the location of 
entrapped drugs (redrawn from Lembo and Cavalli, 2010) 
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Liposomes differ based on the different type of phospholipid used, lipid 
composition, method of preparation, surface charge, lamellarity and size (Du Plessis 
et al., 1994). Liposomes have a characteristic Tc (phase transition temperature), at 
which the liposome membranes transit from the gel phase to liquid crystalline phase, 
and the encapsulated drugs are released from the vesicles (Li et al., 2015). The Tc 
depends on the nature of the polar head group, the length of the hydrocarbon chains, 
the degree of saturation of the hydrocarbon chains and the purity of phospholipids (Li 
et al., 2015). In liposomes system, hydrophobic drugs will be encapsulated in the 
hydrophobic region of the phospholipid bilayers whereas hydrophilic drugs will be 
entrapped in the aqueous core and between bilayers. The ‘rigidity’ or ‘fluidity’ and 
the charge of the bilayer of the liposome are dependent on the bilayer components 
(Akbarzadeh et al., 2013). 
Liposomes have been widely used for dermal and transfollicular delivery of 
drugs. Du Plessis et al. (1994) found that the particle size influenced the deposition 
of drugs in the skin, for a liposome preparation containing ciclosporin as a model 
drug. They found the intermediate particle size (0.3 µm) studied resulted in the 
highest amount of drug in the deeper skin strata and the receiver chamber for both 
hamster and hairless mouse skin except the pig skin after 24 h using Franz diffusion 
cells. The same was not seen for pig skin because of the lipophilic nature of both 
ciclosporin and the pigskin with the release of ciclosporin to the receiver retarded 
(Du Plessis et al., 1994). 
Esposito et al. (1998) found the permeability of a liposome preparation of 
methyl nicotinate through a synthetic membrane was influenced by the charged 
particles, a higher amount of phosphatidylcholine, the smaller size of particles and 
also the higher viscosity of the samples. In the case of the non-extruded sample, the 
permeability was affected by the vesicle size, where smaller size increased the 
permeability rather than the viscosity. However, for extruded samples, the 
permeability was affected by the viscosity of the formulation. 
Flexible liposomes, which are mixtures of lipids and surfactants have been 
studied in order to penetrate the SC (Cevc et al., 1998; Ogunsola et al., 2012). Cevc 
et al. (1998) prepared flexible liposomes, called as Transferosomes® containing 
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soybean phosphatidylcholine, sodium cholate and biocompatible surfactants 
produced liposome dispersion that passed through a filter of much smaller pore size.  
Another study conducted by Ogunsola et al. (2012) prepared flexible 
liposomes with egg phosphatidylcholine and Tween 80 or sodium cholate or ethanol 
with the mean size range from 74 – 110 nm that passed through the filter with 50 nm 
pore size.  In vitro penetration studies found that fluorescent-tagged lipid to 
liposomes with a higher amount of Tween 80 (60 or 68%) showed penetration of 
fluorescent-tagged lipid flexible liposomes into the epidermis of hairless guinea pig 
and excised human skin.  
Although liposomes have been used for drug delivery to reduce the toxicity of 
drugs, increase efficacy and stability and site-specific drug delivery, there are also 
some disadvantages. Conventional liposomes have poor drug loading capacity, poor 
stability, production costs are high, and the use of volatile solvents are required in 
their preparation. 
1.11.2 Polymer-based carrier for drug delivery 
Figure 1.17 shows different types of the polymer-based carrier for drug 
delivery. Hydrogels are produced by a group of polymeric materials having a 
hydrophilic structure which is capable of holding large amounts of water in their 
three-dimensional networks (Ahmed, 2015). Drugs can be loaded into the gel matrix 
and the drug release rate is dependent on diffusion of the small molecule or 
macromolecule through the gel network (Hoare and Kohane, 2008). Many studies 
have reported incorporation of nanoparticles or microparticles into a hydrogel in 
order to improve dermal delivery. Bhaskar et al. (2009) produced flurbiprofen loaded 
SLNs or NLCs (average particles sizes of less than 300 nm) incorporated with a 
hydrogel and found that sustained drug release over a period of 24 h was higher with 
the SLNs and NLCs hydrogel compared to SLNs and NLCs without hydrogel.  
Biodegradable polymers such as poly(D,L-lactic acid) (PLA), poly(D,L-
lactic-co-glycolic acid) (PLGA), and poly (ε-caprolactone) (PCL) and their 
copolymers diblock or multiblock with poly(ethylene glycol) (PEG) have been 
commonly used to form polymeric nanocarriers (polymeric micelles, capsules, 
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spheres) in order to encapsulate a variety of therapeutic compounds (Chan et al., 
2010). Polymeric nanocarriers such as micelles are formulated by self-assembly of 
block copolymers consisting of two or more polymer chains with different 
hydrophobicities (Chan et al., 2010) such amphiphilic polymers which have both 
hydrophilic blocks and hydrophobic blocks can be used for drug delivery where 
normally the hydrophobic blocks form the core to minimize their exposure to 
aqueous surroundings  (Chan et al., 2010; Trivedi and Kompella, 2010).  
 
 
 
 
 
 
 
 
Figure 1.17 Different structures of nanocarriers (redrawn from Janssen et al., 
2014) 
 
Nanospheres (matrix system) or nanocapsules (reservoir system) are both in 
the polymeric nanoparticle group. Nanocapsules are polymeric nanoparticles 
containing either an oily or aqueous core surrounded by a polymeric shell 
(combination with a mixture of lipophilic and hydrophilic surfactants), whereas 
nanospheres are polymer-only matrix systems (Elmowafy et al., 2017). Nanospheres 
and nanocapsules are able to modify the activity of drugs, sustain and control drug 
release, and increase the drug adhesivity in the skin (Guterres et al., 2007).     
Elmowafy et al. (2017) reported indomethacin loaded into polymeric 
nanocapsules and nanospheres produced a higher cumulative amount of drug in 
human skin compared to a marketed product (indomethacin in gel) at 24 h. They 
= drug 
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Micelle Hydrogel 
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found significantly higher skin permeation from nanocapsules of indomethacin 
compared to nanospheres. Even though nanocapsules had a larger particle size (186 – 
193 nm) than nanospheres (138 - 142 nm), higher permeability was attributed to 
higher nanocapsules deformability than nanospheres (rigid matrix system).  
Biodegradable, natural polymers are the first choice materials for producing 
polymeric nanoparticles, in order to minimise toxicity. In some studies, investigators 
have developed new compounds for nanoparticle production by conjugating the 
polymer with drugs especially for tumour targeting (Dragojevic et al., 2015). 
Ringsdorf (1975) introduced a model for pharmacologically active polymers, 
consisting of a biocompatible polymer backbone bound to three components; 
solubilizer, drug which is bound to the polymeric backbone via a linker, and a 
targeting moiety whose function is to provide transport to a desired physiological 
destination or to bind to a particular biological target (Larson and Ghandeharia, 
2012). Castleberry et al. (2017) prepared all-trans retinoic acid conjugated with 
polyvinyl alcohol and produced sustained controlled delivery of active up to 10 days 
and significantly increased dermal accumulation of the all-trans retinoic acid in the 
pig skin. Polymer-conjugated drugs generally exhibit prolonged half-life, higher 
stability, water solubility, lower immunogenicity and antigenicity and often also 
specific targeting to tissues or cells (Pasut and Veronese, 2007).  
The disadvantages of polymeric nanoparticles are the need for the approval 
by regulatory authorities on the safety issues, and also their high production costs 
(Bala et al., 2004). 
1.11.3 Lipid nanocarriers 
There are different types of lipid nanocarriers used for drug delivery system. 
Nanoemulsions comprise liquid mixtures of oil, water, surfactant and sometimes a 
co-surfactant having a droplet size in the range of 50 - 200 nm (Kong et al., 2011).  
In terms of production, the concentration of surfactant used is much lower (3-10%) 
compared to microemulsion preparation (more than 20%) (Bouchemal et al., 2004). 
Borges et al. (2013) found a dapsone-loaded nanoemulsion with isopropyl myristate 
as the oil phase promoted high in vitro epidermal permeation using Franz cells on 
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porcine ear epidermis. Hussain et al. (2016) formulated an amphotericin B-loaded 
nanoemulsion (mean droplet size 76 nm) and found a higher skin percutaneous 
permeation flux rate through rat skin as compared to drug solution using Franz 
diffusion cell. Amphotericin B in solution showed the highest release at 2 h, while 
amphotericin B-loaded nanoemulsion gel showed slower release compared to 
amphotericin B loaded-nanoemulsion alone. However, there are some disadvantages 
of nanoemulsions such as limited controlled release properties due to the liquid state 
of the carrier (Martins et al., 2007).  
A second type of lipid-based nanocarriers is solid lipid nanoparticles (SLNs).  
In the 1990s, these were introduced as drug carrier system (Müller et al., 2002), and 
produced by replacing the liquid lipid (oil) of an emulsion by solid lipids or a blend 
of solid lipids (Müller et al., 2007). SLNs have a mean particle size of between 50 
and 1000 nm (nanoparticles) (Müller et al., 2000). SLNs have been produced for 
pharmaceutical, traditional Chinese medicine and cosmetic applications. SLNs have 
been used to deliver bioactive ingredients such as vitamin A (Jenning et al., 2000), 
rifampicin, isoniazid and pyrazinamide (Pandey and Khuller, 2005), oridonin  (Zhang 
et al., 2006), isotretinoin (Liu et al., 2007), Artemisia arborescens essential oil (Lai et 
al., 2007), repaglinide (Vijayan et al., 2010), virgin coconut oil (Noor et al., 2013), 
docetaxel (Naguib et al., 2014) and olanzapine (Iqbal et al., 2017). Different methods 
have been proposed in order to produce SLNs including high-pressure homogeniser, 
solvent evaporation, ultrasonication or melt dispersion techniques (Gasco, 1993; 
Müller et al., 2000; Trotta et al., 2003).   
The second generation of SLNs is called as nanostructured lipid carriers 
(NLCs). NLCs are produced by incorporating blends of solid lipids and liquid lipids 
(oils) (Pardeike et al., 2009). Some examples of liquid lipid used in NLCs production 
are medium chain triglyceride such as oleic acid. Figure 1.18 shows the structural 
differences between SLNs and NLCs. Due to the main ingredients in SLNs being 
solid lipid (at room temperature), SLNs are in a highly crystalline form, limiting drug 
loading, whereas NLCs (combination of solid and liquid lipid) have a less crystalline 
structure, increasing drug loading. NLCs were introduced in order to overcome some 
of the problems associated with SLNs by increasing drug loading and reducing the 
burst release of drugs (Wissing and Müller, 2002; Hommoss, 2008; Silva et al., 
2009). The mean particle size for NLCs is usually less than 1000 nm. 
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Figure 1.18 Schematic illustration of SLN and NLC structures (modified from 
Beloqui et al., 2016)  
 
Several different types of solid lipid can be used in the production of SLNs 
and NLCs. The term ‘solid lipid’ includes fatty acids (e.g. myristic, stearic and 
palmitic acid), triglyceride (e.g. tripalmitin and tristearin), diglyceride (e.g. glyceryl 
behenate), monoglyceride (e.g. glyceryl monostearate), steroid (e.g. cholesterol) and 
waxes (e.g. cetyl palmitate and beeswax). Lipids used in SLNs or NLCs are generally 
regarded as safe (GRAS) (Attama et al., 2012). Different types of solid lipid have 
various degrees of crystallisation that may impact the drug entrapment efficiency and 
loading, size and charge of the resulted carriers. The lipid particle matrix is solid at 
both room and body temperatures (Müller et al., 2014).  
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1.12 Aim of the study 
The aim of this project is to prepare and characterise dutasteride-loaded 
nanostructured lipid carriers (DST-NLCs), coated with chitosan oligomer conjugated 
with stearic acid, and lauric acid to enhance local drug delivery and reduce toxicity 
(Figure 1.19).  
 
 
 
 
 
 
 
 
  
 
 
Figure 1.19 Schematic representation of DST-NLCs coated with CSO-SA or 
CSO-LA to be prepared and characterised in this project 
 
Figure 1.20 shows the flow of the project outlined in this thesis. The project 
began with the conjugation and characterisation of CSO-SA and CSO-LA (Chapter 
2). This was followed by optimisation of the formulation and manufacture of 
nanoparticles containing dutasteride and their characterisation (Chapter 3) and the in 
vitro studies (Chapter 4). Dutasteride was chosen as a drug having anti-androgenic 
activity, exhibiting Type I and Type II 5α-reductase inhibitions.  
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Figure 1.20 Schematic diagram of overall preparation, characterisation and in 
vitro study of dutasteride-loaded nanostructured lipid carrier coated with 
chitosan oligomer-stearic or lauric acid 
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